Flamel Technologies S.A. (NASDAQ:AVDL) had its price target upped by stock analysts at Ladenburg Thalmann Financial Services from $27.00 to $30.00 in a research report issued on Thursday. Ladenburg Thalmann Financial Services’ price objective indicates a potential upside of 234.82% from the stock’s previous close.

A number of other brokerages have also recently commented on AVDL. Zacks Investment Research raised shares of Flamel Technologies from a “hold” rating to a “buy” rating and set a $12.00 price objective on the stock in a research note on Monday, July 17th. Roth Capital set a $15.00 price objective on shares of Flamel Technologies and gave the company a “buy” rating in a research note on Wednesday, August 9th. One analyst has rated the stock with a sell rating and four have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $19.83.

Flamel Technologies (AVDL) traded up 6.04% during trading on Thursday, reaching $8.96. 211,009 shares of the company were exchanged. The firm has a market capitalization of $359.15 million, a PE ratio of 9.46 and a beta of 1.39. Flamel Technologies has a 12 month low of $8.14 and a 12 month high of $14.70. The stock has a 50 day moving average price of $9.23 and a 200 day moving average price of $9.88.

Flamel Technologies (NASDAQ:AVDL) last issued its quarterly earnings data on Tuesday, August 8th. The company reported $0.19 EPS for the quarter, beating the Zacks’ consensus estimate of $0.05 by $0.14. The firm had revenue of $46.30 million for the quarter, compared to analysts’ expectations of $45.17 million. Flamel Technologies had a net margin of 21.13% and a return on equity of 29.84%. Flamel Technologies’s revenue was up 19.0% on a year-over-year basis. On average, analysts expect that Flamel Technologies will post $1.11 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This report was posted by American Banking News and is the sole property of of American Banking News. If you are accessing this report on another site, it was copied illegally and reposted in violation of international trademark and copyright law. The correct version of this report can be read at https://www.americanbankingnews.com/2017/09/07/flamel-technologies-s-a-avdl-price-target-increased-to-30-00-by-analysts-at-ladenburg-thalmann-financial-services.html.

In other Flamel Technologies news, major shareholder Healthcare Master Fun Broadfin sold 261,000 shares of the firm’s stock in a transaction dated Friday, June 23rd. The shares were sold at an average price of $10.68, for a total transaction of $2,787,480.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Guillaume Cerutti sold 26,560 shares of the firm’s stock in a transaction dated Thursday, June 15th. The stock was sold at an average price of $10.46, for a total transaction of $277,817.60. Following the sale, the director now directly owns 23,440 shares in the company, valued at $245,182.40. The disclosure for this sale can be found here. 5.07% of the stock is owned by company insiders.

Several institutional investors have recently added to or reduced their stakes in AVDL. Janus Henderson Group PLC acquired a new stake in shares of Flamel Technologies during the 2nd quarter worth about $24,100,000. Russell Investments Group Ltd. acquired a new stake in shares of Flamel Technologies during the 1st quarter worth about $3,654,000. Acadian Asset Management LLC boosted its stake in shares of Flamel Technologies by 9.7% during the 2nd quarter. Acadian Asset Management LLC now owns 1,672,207 shares of the company’s stock worth $18,444,000 after purchasing an additional 147,907 shares during the last quarter. OxFORD Asset Management LLP boosted its stake in shares of Flamel Technologies by 62.7% during the 2nd quarter. OxFORD Asset Management LLP now owns 334,881 shares of the company’s stock worth $3,694,000 after purchasing an additional 129,044 shares during the last quarter. Finally, JPMorgan Chase & Co. acquired a new stake in shares of Flamel Technologies during the 2nd quarter worth about $733,000. 69.09% of the stock is currently owned by institutional investors.

About Flamel Technologies

Flamel Technologies SA is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its polymer based technology. The Company has a balanced business model consisting of an Unapproved Marketed Drugs (UMDs) business with over two approved products in the United States, Bloxiverz (neostigmine methylsulfate injection) and Vazculep (phenylephrine hydrochloride injection) that are marketed; a branded pediatric business, and a branded business, focusing on the development of products utilizing Flamel’s drug delivery platforms.

Receive News & Ratings for Flamel Technologies S.A. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flamel Technologies S.A. and related companies with MarketBeat.com's FREE daily email newsletter.